Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies

European Journal of Haematology

Volumn 89, Issue 2, 2012, Pages 111-119

  Mariotti, Jacopo ^a,b   Spina, Francesco ^a,b   Carniti, Cristiana ^a   Anselmi, Giovanni ^c   Lucini, Davide ^a,b   Vendramin, Antonio ^a,b   Pregliasco, Fabrizio ^c   Corradini, Paolo ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Dipartimento di Scienze Veterinarie e Sanità Pubblica   (Italy)

Author keywords

A (H1N1) virus; Hematologic malignancies; Immunocompromised host; Immunologic response; Vaccination

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEMAGGLUTINATION INHIBITION TEST; HEMATOLOGIC MALIGNANCY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; T LYMPHOCYTE; TREATMENT RESPONSE; VACCINATION;

ADULT; AGED; ANTIBODIES, VIRAL; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; T-LYMPHOCYTES; TIME FACTORS; VACCINATION;

EID: 84863817927     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01793.x     Document Type: Article

References (38)

1. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009;9:493-504.
2. Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med 2007;28:222-42.
3. Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, Champlin RE, Aguilera EA, Tarrand JJ, Raad II. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006;85:278-87.
4. Ljungman P. Respiratory virus infection in stem cell transplant recipients: the European experience. Biol Blood Marrow Transplant 2001;7(SUPPL.):5S-7S.
5. Center for Disease Control and Prevention. H1N1 Flu: International Situation Update. 2009. Available from URL: Accessed on October 17, 2009.
6. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010;362:1708-19.
7. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009;302:1872-9.
8. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009;302:1896-902.
9. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009;361:1935-44.
10. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009;361:2414-23.
11. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009;361:2405-13.
12. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009;361:2424-35.
13. De Lavallade H, Garland P, Sekine T, et al. Repeated vaccination is required to optimise seroprotection against H1N1 in the immunocompromised host. Haematologica 2011;96:307-14.
14. Issa NC, Marty FM, Gagne LS, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011;17:434-8.
15. Talbot HK, Keitel W, Cate TR, et al. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine 2008;26:4057-61.
16. Wu J, Fang HH, Chen JT, et al. Immunogenicity, safety, and cross-reactivity of an inactivated, an inactivated, adjuvated, prototype pandemic influenza (H5N1) vaccine: a phase II, double blind, randomized trial. Clin Infect Dis 2009;48:1087-95.
17. Wehler TC, Karg M, Distler E, Konur A, Nonn M, Meyer RG, Huber C, Hartwig UF, Herr W. Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression. J Immunol Methods 2008;339:23-37.
18. Kim DH, Chang WS, Lee YS, Lee KA, Kim YK, Kwon BS, Kang CY. 4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation. J Immunol 2008;180:2062-8.
19. Baessler T, Charton JE, Schmiedel BJ, Grünebach F, Krusch M, Wacker A, Rammensee HG, Salih HR. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010;115:3058-69.
20. Committee for Proprietary Meicinal Products. Note for Guidance on Harmonisation of Requirements for influenza Vaccines. London: European Medicines Agency, 1996. (Publication no CPMP/BWP/214/96). Available from URL: Accessed on 9 September 2009.
21. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006;24:1159-69.
22. Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol 2010;28:2481-90.
23. Ortbals DW, Liebhaber H, Presant CA, Van Amburg AL III, Lee JY. Influenza immunization of adult patients with malignant diseases. Ann Intern Med 1977;87:552-7.
24. Machado CM, Cardoso MR, da Rocha IF, Boas LS, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant 2005;36:897-900.
25. Mazza JJ, Yale SH, Arrowood JR, Reynolds CE, Glurich I, Chyou PH, Linneman JG, Reed KD. Efficacy of the influenza vaccine in patients with malignat lymphoma. Clin Med Res 2005;3:214-20.
26. Brydak LB, Machala M, Centkowski P, Warzocha K, Biliński P. Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma. Vaccine 2006;24:6620-3.
27. EMEA. Note for Guidance on Harmonization of Requirements for Influenza Vaccines. European Committee for Proprietary Medicinal Products, 1997 (CPMP/BWP/214/96).
28. Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427-37.
29. Noonan KA, Ferguson A, Emerling A, Rudraraju L, Huff CA, Schafer PH, Borrello IM. Lenalidomide augments immune responses to prevnar vaccination in relapsed myeloma patients: implications for cancer and infectious vaccines. Blood (ASH Annual Meeting Abstracts) 2009;114:Abstract 1864.
30. Pauksen K, Linde A, Hammarström V, Sjölin J, Carneskog J, Jonsson G, Oberga G, Engelmann H, Ljungman P. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin Infect Dis 2000;30:342-8.
31. Gelinck LB, van den Bemt BJ, Marijt WA, van der Bijl AE, Visser LG, Cats HA, Rimmelzwaan GF, Kroon FP. Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible. Vaccine 2009;27:2469-74.
32. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol 2005;130:96-8.
33. Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993;11:1-5.
34. Gueller S, Allwinn R, Mousset S, Martin H, Wieters I, Herrmann E, Serve H, Bickel M, Bug G. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011;17:1546-50.
35. Mohty B, Bel M, Vukicevic M, et al. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica 2011;96:896-904.
36. Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant 2008;42:637-41.
37. McElhaney JE, Hooton JW, Hooton N, Bleackley RC. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine 2005;23:3294-300.
38. Long BR, Michaelsson J, Loo CP, Ballan WM, Vu BA, Hecht FM, Lanier LL, Chapman JM, Nixon DF. Elevated frequency of gamma interferon-producing NK cells in healthy adults vaccinated against influenza virus. Clin Vaccine Immunol 2008;15:120-30.